7 Best Hematology Startups to Watch in 2025

The Definitive Seedtable Ranking of Hematology Startups

We track 71,000+ companies and rank them dynamically using our Seedtable Score – a score that uses quantitative and qualitative data points to signal the momentum behind a company. We then monitor the list manually leveraging our expertise as founders and investors.

There are 7 start-ups with an aggregate funding of $1.2b. The average funding per company in this subset is $169.3m.

Last update to the database: Feb 18, 2025. See changelog.

Track over 71,000 companies

Discover
Fast-growing Global startups

Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.

Pricing + Sign up
Freenome logo

Freenome

Freenome is a San Francisco-based company which uses genetic analysis for early cancer detection and risk assessment.

8

Funding Rounds

$967.6m

Money raised

Sanguine (company) logo

Sanguine (company)

Sanguine is a company that has the mission to accelerate medical research by eliminating the barriers to patient participation.

1

Funding Rounds

$1.0m

Money raised

Scopio Labs logo

Scopio Labs

AI-powered, FDA-cleared blood cell morphology platform replaces manual lab microscopy, helping hematologists and hematopathologists to detect cancers and blood-related diseases.

2

Funding Rounds

$18.5m

Money raised

NuvOx Pharma logo

NuvOx Pharma

NuvOx Pharma is an oxygen therapeutics company founded in 2008 by David Wilson.

10

Funding Rounds

$13.5m

Money raised

Prolong Pharmaceuticals logo

Prolong Pharmaceuticals

A biotechnology company developing treatments for hematology and oncology diseases

1

Funding Rounds

$30.0m

Money raised

Hemarina logo

Hemarina

The Hemarina technological platform is based on the peculiarities of the purified hemoglobin of lugworms, Arenicola marina . Its structure is comparable to that of human hemoglobin, however it is distinguished by: its extracellular character (it is not contained in a red blood cell), and therefore universal (compatibility with all blood groups) its ability to bind 40 times more oxygen than human hemoglobin its particularly small size: 250 times smaller than the human red blood cell

2

Funding Rounds

$4.8m

Money raised

Sangart logo

Sangart

A biopharmaceutical company developing scientific, clinical and commercial oxygen-therapeutic agents

2

Funding Rounds

$150.0m

Money raised